Best Life Sciences Companies in Beverly, United States
The 35 best Life Sciences companies in Beverly, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Hamilton Thorne.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Beverly
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Hamilton Thorne Precision laser devices and advanced image analysis systems for the fertility, stem cell and development… | $34M | 75 mo ago | 77 | — | Acquired | WordPress Block EditorWordPressMySQL+27 | 32 patents Modular laser beam manipulation optics for microscopy and microfabrication | — |
| 2 | LexaGene Developer of automated instrumentation for pathogen detection | $24M | 55 mo ago | 45 | — | Public | — | 22 patents Automated nucleic‑acid extraction and low‑volume sample‑prep cartridges for molecular diagnostics | — |
| 3 | seqWell Provider of NGS-based reagents and kits for life sciences research | $21M | 24 mo ago | 38 38 → 38 (+0%) | Jack Leonard Co-Founder & CTO | Series C | WordPressMySQLPHP+32 | 27 patents Nucleic acid library preparation, normalization, and engineered transposase tools for NGS. | 1 launch |
| 4 | Velico Developer of blood and plasma products for transfusion | $19M | 108 mo ago | 33 | — | Funding Raised | WordPressMySQLPHP+19 | — | — |
| 5 | Akston Biosciences Developer of therapeutics for use in autoimmune Type 1 diabetes prevention, ultra-long-acting insulin… | $14M | 53 mo ago | 61 | — | Series B | WordPress Site EditorWordPressMySQL+11 | 165 patents Therapeutic Fc‑fusion biologics for metabolic, oncology and immunotherapy applications | — |
| 6 | TellBio Developer of liquid biopsy for the treatment and detection of cancer | $10M | 24 mo ago | 5 | Pritesh Gandhi CEO | Series A | — | — | — |
| 7 | Sage Science Laboratory and research-related technologies | $8M | 49 mo ago | 16 | — | Seed | — | — | — |
| 8 | Medicinal Genomics Provider of microbial and plant pathogen testing for multiple industries | $8M | 65 mo ago | 30 30 → 42 (+40%) | Kevin McKernan Founder | Acquired | WordPressMySQLPHP+29 | 26 patents Molecular diagnostics for microbial and psychoactive compound detection in cannabis and psilocybin fungi | — |
| 9 | BioHelix Develops novel molecular diagnostics using isothermal amplification technologies | $6M | 206 mo ago | 22 | — | Acquired | — | 16 patents Helicase-dependent RNA target amplification and detection technologies | — |
| 10 | Enzymatics Manufacturer of enzymes and DNA sample preparation kits for next-generation sequencing | $5M | 157 mo ago | 140 140 → 72 (-49%) | Stephen Picone Co-Founder & CSO | Acquired | — | 7 patents Enzymatic DNA library prep and thermostable polymerase‑based DNA synthesis technologies | — |
| 11 | Endolytix Technology Developer of therapeutics for nontuberculous mycobacterial infections | $5M | 25 mo ago | 16 | — | Funding Raised | — | 5 patents Antimicrobial therapeutics for intracellular bacterial and actinomycetia infections | — |
| 12 | Glycologix Developer of biopolymers for the protection and repair of soft tissues | $3M | 9 mo ago | 7 | Thomas Jozefiak Scientific Founder | Seed | — | 25 patents Sulfated glycosaminoglycan biomaterials that mimic proteoglycans for tissue engineering applications | — |
| 13 | Salzman Group Developer of small molecule based therapeutics for the treatment of Crohn's disease | $2M | 172 mo ago | — | Andrew Salzman Co-Founder & CEO | Acqui-Hired | — | 6 patents Therapeutic nitroxide prodrugs for oxidative stress and endothelial dysfunction treatment. | — |
| 14 | VirTech Bio Biotech developing human-derived HBOC platform for hemorrhagic shock and organ transplants | $500K | 73 mo ago | 8 | Matias Vidal CEO | Seed | — | — | — |
| 15 | Prospective Research Online casino offering various games, bonuses, and strategies for players | $200K | 49 mo ago | 2 | Dakota Hamill Founder and CEO | Seed | — | — | — |
Top 12 Life Sciences companies in Beverly
#1
Seed · Beverly, Massachusetts · founded 2016 · 7 employees$3.2Mraised▾
Developer of biopolymers for the protection and repair of soft tissues. The company is developing a non-systemic, highly cross-linked chondroitin sulfate (CS) based biopolymer platform for soft tissue protection and repair which is focused on a broad range of medical needs such as interstitial cystitis, dry eye, surgical adhesion prevention, osteoarthritis, disk disease, and wound repair.
- Dec 2025Seed$800K
- Dec 2025Conventional Debt—
- Apr 2024Seed$1.5M
- May 2023Seed$1.8M
#2
Series C · Beverly, Massachusetts · founded 2014 · 38 employees$21.4Mraised▾
Provider of NGS-based reagents and kits for life sciences research. The company has developed a plexWell platform, transformative technology for parallelized library prep that allows for simple, easy multiplexing of 100s to 1000s of distinct samples. The company's Illumina-compatible plexWell Library Preparation technology permits an order-of-magnitude improvement in the number of samples that can be prepared and readily sequenced on benchtop NGS instruments.
- Sep 2024Series C$3.1M
- Sep 2023Series C$3.4M
- Apr 2022Series C$7M
- Jan 2020Series B$9M
#3
Series A · Beverly, Massachusetts · founded 2019 · 5 employees$9.7Mraised▾
Developer of liquid biopsy for the treatment and detection of cancer. The company offers a TellDx diagnostic platform that detects circulating tumor cells and a TellRx therapeutics platform that generates novel anti-cancer drugs by using the study of CTCs.
- Sep 2024Series A$1M
- Jun 2024Series A$1.2M
- Jun 2024Conventional Debt—
- Oct 2023Series A$1M
#4
Funding Raised · Beverly, Massachusetts · founded 2020 · 16 employees$5Mraised▾
Developer of novel therapeutics designed to cure antibiotic infections. The company provides therapies that are effective in killing pathogenic bacteria including multidrug-resistant bacteria, enabling the healthcare industry to address the most resistant antibiotic infections that are difficult to access and treat.
- Jul 2024Conventional Debt$5M
#5
Public · Beverly, Massachusetts · founded 2007 · 45 employees$24.2Mraised▾
Developer of automated instrumentation for pathogen detection. The company develops automated instrumentation that finds applications in pathogen detection in food, aquaculture animals, water quality monitoring, veterinary diagnostics, and other markets such as the pharmaceutical industry, inspecting imports, and more. The company has developed a patented microfluidic technology that utilizes single-use disposable cartridges to concentrate and purify genetic material from samples and microfluidics to perform molecular analysis.
- Feb 2022Post IPO$5M
- Sep 2020Post IPO$10.1M
- Nov 2019Post IPO$5.1M
- Apr 2019Post IPO$115.2K
#6
Acquired · Beverly, Massachusetts · founded 2002 · 77 employees$34.1Mraised▾
Hamilton Thorne is a provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and development biology research markets. The laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF (In Vitro Fertilization) procedures. Currently, provides 5 laser products and there are a few in development. Its CASA (Computer Assisted Sperm Analysis) image analysis systems are designed to improve studies of reproductive cells in the human fertility, animal sciences and reproductive toxicology fields. The customers include major research labs both in academia and pharmaceutical companies.
- May 2020Post IPO$5.1M
- Sep 2019Conventional Debt$7.5M
- Sep 2018Post IPO$10M
- Oct 2017Post IPO$150K
#7
Series B · Beverly, Massachusetts · founded 2011 · 61 employees$13.8Mraised▾
Developer of therapeutics for use in autoimmune Type 1 diabetes prevention, ultra-long-acting insulin therapy, and oncology. Its drug pipeline includes AKS-107, disrupt insulin autoimmunity to prevent type 1 diabetes (T1D); AKS-130, ultra-long-acting, once-per-week insulin for treating Type 1 and Type 2 Diabetes; AKS-231, next-generation smart glucose-responsive insulin for treating Type 1 and Type 2 Diabetes; AKS-301 for controlled hypoglycemia to enhance anti-tumor cancer therapy.
- Apr 2022Series B$5.2M
- May 2021Series A$1M
- May 2020Series A$5.1M
- Jun 2019Seed$2.5M
#8
Seed · Beverly, Massachusetts · founded 2005 · 16 employees$7.9Mraised▾
Sage Science develops products for the life sciences research markets. Their product portfolio includes products to perform DNA or cDNA sizing and protein fractionation; Pippin Prep for targeted DNA sizing; BluePippin for large DNA sizing and protein fractionation; and SageELF for whole-sample fractionation of DNA or protein samples.
- Aug 2022Grant (prize money)$1.3M
- May 2019Grant (prize money)$1.8M
- Nov 2018Grant (prize money)$1.8M
- Jul 2015Grant (prize money)$1.3M
#9
Funding Raised · Beverly, Massachusetts · founded 1992 · 33 employees$19Mraised▾
Developer of blood and plasma products for transfusion. The company is developing a proprietary platform technology for manufacturing spray dried human plasma called FrontlineODP for pre-hospital transfusions.
- Sep 2017Grant (prize money)$19M
#10
Acquired · Beverly, Massachusetts · founded 2011 · 30 employees$7.7Mraised▾
Provider of microbial and plant pathogen testing for multiple industries. The company offers genomic services, including microbiome sequencing, pathogen identification, and plant genotyping. It serves testing laboratories, manufacturers, and growers. Industries served include supplements, natural products, cannabis, and food.
- Apr 2021Series A$2.7M
- Nov 2017Series A$5M
#11
Acquired · Beverly, Massachusetts · founded 2004 · 22 employees$5.9Mraised▾
Biohelix, a spin-off from New England Biolabs, develops novel molecular diagnostic and research solutions using isothermal amplification technologies. It has a suite of proprietary technologies, including helicase-dependent amplification (HDA) using isothermal PCR, amplification technologies, and technology for whole-genome amplification that has been licensed from Harvard. Clinical diagnostic products include the "instrument-free" IsoAmp range of molecular assays for infectious diseases such as Bordetella, C. difficile, Group A and B Streptococcus, herpes (both HSV 1 & 2) and Trichomonas, as well as products for the detection of genetic diseases such as hereditary hemochromatosis and factor V Leiden. In addition, the company also specialized in life science research products such as the IsoAmp range of amplification kits for PCR, the PrimeNavigator series of extremely thermostable single-stranded DNA binding proteins, and thermostable mesophilic DNA helicases. In May 2013, Quidel acquired Biohelix for $10M upfront plus additional milestone payments.
- Jul 2009Grant (prize money)$805.7K
- Mar 2009Grant (prize money)$2.8M
- Mar 2009Grant (prize money)$2.1M
- Feb 2009Grant (prize money)$143.6K
#12
Acquired · Beverly, Massachusetts · founded 2006 · 140 employees$5.4Mraised▾
Manufacturer of enzymes and DNA sample preparation kits for next-generation sequencing. The company also has the ability to develop a custom reagent or formulation to meet a specific set of customer requirements. The company also provides DNA sample preparation kits for NGS sequencing (Illumina, Ion Torrent).
- Aug 2013Series A$3.8M
- Sep 2006Convertible Debt$1.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.